Edition:
India

DexCom Inc (DXCM.OQ)

DXCM.OQ on NASDAQ Stock Exchange Global Select Market

321.09USD
2:29am IST
Change (% chg)

$5.22 (+1.65%)
Prev Close
$315.87
Open
$318.99
Day's High
$324.53
Day's Low
$314.65
Volume
372,155
Avg. Vol
313,061
52-wk High
$456.23
52-wk Low
$182.15

Latest Key Developments (Source: Significant Developments)

Dexcom Q3 Non-GAAP Earnings Per Share $0.94
Wednesday, 28 Oct 2020 

DexCom Inc ::DEXCOM REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $0.94.Q3 REVENUE $500.9 MILLION VERSUS REFINITIV IBES ESTIMATE OF $480.1 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $0.65 -- REFINITIV IBES DATA.Q3 GAAP EARNINGS PER SHARE $0.73.SEES FY 2020 REVENUE OF ABOUT$1.900 BILLION (29% GROWTH).SEES FY 2020 ADJUSTED EBITDA MARGIN TO MEET OR EXCEED 26%.  Full Article

DexCom Signs Multi-Year Collaboration Agreement With University Of Virginia
Thursday, 24 Sep 2020 

Sept 24 (Reuters) - DexCom Inc ::DEXCOM SIGNS MULTI-YEAR COLLABORATION AGREEMENT WITH THE UNIVERSITY OF VIRGINIA TO ADVANCE TYPE 1 AND TYPE 2 DIABETES RESEARCH.DEXCOM INC - PARTNERSHIP WILL COMMENCE IN LATE 2020.DEXCOM INC - DEXCOM WILL PROVIDE RESEARCH FUNDING TO UNIVERSITY OF VIRGINIA OVER A FIVE-YEAR PERIOD FOR DIABETES-CENTERED RESEARCH AND CLINICAL TRIALS.  Full Article

Dexcom Reports Q2 Earnings Per Share $0.48
Wednesday, 29 Jul 2020 

July 28 (Reuters) - DexCom Inc ::DEXCOM REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS.Q2 NON-GAAP EARNINGS PER SHARE $0.79.Q2 REVENUE $451.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $415.7 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $0.35 -- REFINITIV IBES DATA.Q2 GAAP EARNINGS PER SHARE $0.48.SEES 2020 REVENUE OF APPROXIMATELY $1.850 BILLION.SEES 2020 ADJUSTED EBITDA MARGIN TO MEET OR EXCEED 24%.DEXCOM - AS OF JUNE 30, HELD $2.51 BILLION IN CASH AND MARKETABLE SECURITIES AND REVOLVING CREDIT FACILITY REMAINS UNDRAWN.FY2020 REVENUE VIEW $1.80 BILLION -- REFINITIV IBES DATA.  Full Article

DexCom Says Health Canada Authorizes Interim Use Of Dexcom G6 CGM by Pregnant Women
Thursday, 16 Jul 2020 

July 16 (Reuters) - DexCom Inc ::HEALTH CANADA AUTHORIZES INTERIM USE OF DEXCOM G6 CGM BY PREGNANT WOMEN IN RESPONSE TO THE COVID-19 PANDEMIC.  Full Article

Dexcom Prices Offering Of Upsized $1.05 Billion Of 0.25% Convertible Senior Notes
Tuesday, 12 May 2020 

DexCom Inc ::DEXCOM PRICES OFFERING OF UPSIZED $1.05 BILLION OF 0.25% CONVERTIBLE SENIOR NOTES.DEXCOM INC - PRICING OF ITS OFFERING OF $1.05 BILLION 0.25% CONVERTIBLE SENIOR NOTES DUE 2025.DEXCOM INC - AGGREGATE PRINCIPAL AMOUNT OF OFFERING WAS INCREASED FROM PREVIOUSLY ANNOUNCED OFFERING SIZE OF $850.0 MILLION.DEXCOM INC - NOTES WILL MATURE ON NOVEMBER 15, 2025.  Full Article

Dexcom Reports Proposed Offering Of $850.0 Million Of Convertible Senior Notes
Monday, 11 May 2020 

May 11 (Reuters) - DexCom Inc ::DEXCOM ANNOUNCES PROPOSED OFFERING OF $850.0 MILLION OF CONVERTIBLE SENIOR NOTES.DEXCOM INC - TO OFFER $850.0 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2025 IN A PRIVATE PLACEMENT.  Full Article

DexCom Reports Q1 2020 Financial Results
Wednesday, 29 Apr 2020 

April 28 (Reuters) - DexCom Inc ::DEXCOM REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS.Q1 NON-GAAP EARNINGS PER SHARE $0.44.Q1 REVENUE $405.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $358 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.15 -- REFINITIV IBES DATA.Q1 GAAP EARNINGS PER SHARE $0.21.TEMPORARILY SUSPENDING ITS 2020 GUIDANCE.AS OF MARCH 31, 2020, CO HELD $1.5 BILLION IN CASH AND MARKETABLE SECURITIES AND CO'S REVOLVING CREDIT FACILITY REMAINS UNDRAWN.  Full Article

Dexcom Reports Q4 Earnings Per Share $1.00
Friday, 14 Feb 2020 

Feb 13 (Reuters) - DexCom Inc ::DEXCOM REPORTS FOURTH QUARTER AND FISCAL YEAR 2019 FINANCIAL RESULTS.Q4 NON-GAAP EARNINGS PER SHARE $1.15.Q4 REVENUE $462.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $442.4 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.74 -- REFINITIV IBES DATA.SEES FY 2020 REVENUE $1.725 BILLION TO $1.775 BILLION.Q4 GAAP EARNINGS PER SHARE $1.00.FY2020 REVENUE VIEW $1.77 BILLION -- REFINITIV IBES DATA.SEES 2020 NON-GAAP ADJUSTED EBITDA MARGIN OF APPROXIMATELY 23%.SEES 2020 NON-GAAP OPERATING MARGIN OF APPROXIMATELY 13%.SEES 2020 NON-GAAP OPERATING MARGIN OF APPROXIMATELY 13%.SEES 2020 GROSS PROFIT MARGIN OF APPROXIMATELY 64%.  Full Article

Dexcom Sees Q4 Revenue Of About $457 Million
Monday, 13 Jan 2020 

Jan 13 (Reuters) - DexCom Inc ::DEXCOM REPORTS RECORD PRELIMINARY, UNAUDITED REVENUE FOR THE FOURTH QUARTER AND FISCAL YEAR 2019 AND PROVIDES INITIAL 2020 OUTLOOK.SEES FY 2019 REVENUE ABOUT $1.47 BILLION.SEES FY 2020 REVENUE ABOUT $1.725 BILLION TO $1.775 BILLION.SEES Q4 2019 REVENUE ABOUT $457 MILLION.Q4 REVENUE VIEW $431.5 MILLION -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $1.44 BILLION -- REFINITIV IBES DATA.FY2020 REVENUE VIEW $1.75 BILLION -- REFINITIV IBES DATA.  Full Article

Lilly To Integrate Dexcom Cgm Into Personalized Diabetes Management System
Monday, 16 Dec 2019 

Dec 16 (Reuters) - Eli Lilly and Co ::LILLY TO INTEGRATE DEXCOM CGM INTO PERSONALIZED DIABETES MANAGEMENT SYSTEM.ELI LILLY - TO USE DEXCOM'S CONTINUOUS GLUCOSE MONITORING DEVICES IN PEN- AND PUMP-BASED PLATFORMS OF SYSTEM BEING DESIGNED TO HELP IMPROVE DIABETES MANAGEMENT.  Full Article